logo-loader
AIM:IXI

IXICO PLC

Receive alerts
Market:
AIM
Market Cap:
£30.14 m
Price
64.00 GBX
Change
1.59%
52 weeks high
98.00
52 weeks low
33.35

In brief

IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease.

Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

Our integrated technology offering encompasses every stage of clinical drug development through to post marketing surveillance and we continue to invest in infrastructure and innovation to support our ambitious growth strategy.  Our competitive advantage is our dedication to address complex unmet clinical research needs by partnering and collaborating with clients and academic partners early in the drug development cycle to identify and validate promising new imaging and digital biomarkers.  

Deep dive We explore the investor case for growth companies

Snapshot

  • Provides data analytics services to interpret brain scans
  • AI-based algorithms aid neurological disease trials

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Ixico in very strong position going forward, says broker

Over the mid- to longer-term, a significant opportunity remains for the company, added the broker.

on 05/20/2020